These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7140514)

  • 1. Conversion from intravenous to oral dosing using sustained-release theophylline tablets.
    Stein GE; Haughey DB; Ross RJ; Vakoutis J
    Drug Intell Clin Pharm; 1982 Oct; 16(10):772-4. PubMed ID: 7140514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from intravenous to sustained-release oral theophylline in pediatric patients with asthma.
    Clarke DF; Werbowsky OL; Grodin MA; Shargel L
    Drug Intell Clin Pharm; 1986 Sep; 20(9):700-3. PubMed ID: 3757784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results.
    Hatton RC; Gotz VP; Robinson JD; Russell WL; Ryerson GG
    Clin Pharm; 1983; 2(4):347-52. PubMed ID: 6883961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
    Yamazaki M; Fukutomi O; Kondo N; Kato Z; Nakashima Y; Shinoda S; Agata H; Kondo T; Imaeda N; Orii T
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
    Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sustained oral theophylline loading. An alternative to intravenous aminophylline therapy.
    Brown DL; Maddux MS; Organek HW; Bauman JL
    Arch Intern Med; 1983 Apr; 143(4):794-6. PubMed ID: 6838301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
    Dockhorn RJ; Cefali EA; Straughn AB
    Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of theophylline clearance in determining chronic oral dosage regimens.
    Slotfeldt ML; Johnson CE; Grambau G; Weg JG
    Am J Hosp Pharm; 1979 Jan; 36(1):66-8. PubMed ID: 758787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a new sustained-release theophylline preparation, TheoBeads, with Theo-Dur tablets in children with asthma.
    Welch MJ; Orgel HA; Meltzer EO; Kemp JP; Gawchik S; Rooklin AR; Tinkelman DG
    J Asthma; 1988; 25(5):269-74. PubMed ID: 3182591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of enteral feedings on sustained-release theophylline absorption.
    Plezia PM; Thornley SM; Kramer TH; Armstrong EP
    Pharmacotherapy; 1990; 10(5):356-61. PubMed ID: 2122422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serum theophylline concentrations following administration of sustained-release beads in applesauce to asthmatic preschool children.
    Leeder JS; Robertson C; Correia J; Isles AF; Levison H; Macleod SM
    Ann Allergy; 1986 Feb; 56(2):133-7. PubMed ID: 3946845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.